Beroni Group Limited Approval for R&D Rebate for Anti-Cancer Drug PENAO

Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure.

The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D activities is less than the expected total expenditure on the Australian R&D activities to which they are scientifically linked.

The PENAO drug manufacture is expected to complete in the first half of 2022. Raw materials have been procured, familiarization studies have been completed and optimization work is progressing well at Aurigene Pharmaceutical Services Ltd, India.

"Aurigene is delighted to partner with PENAO Pty Ltd. In the past 18 years of our work, a key therapy area has been anticancer drug discovery and clinical development. Our technical and infrastructure capabilities provide an integrated drug substance and drug product program for PENAO." said Ravi Venkataramanan, CEO of Aurigene Pharmaceutical Services Ltd, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited (BOM:500124) (NYSE:RDY).

"We are pleased to receive the Australian government's support for our R&D activities, and we hope that the annual rebate signals to investors the rigorous due diligence conducted by the Australian government and our commitment to develop the PENAO drug to potentially meet the unmet medical need of millions of cancer patients worldwide" said Jacky Zhang, CEO of Beroni Group.



About Beroni Group Limited:  

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.



Source:
Beroni Group Limited



Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

The Conversation (0)
B2Gold Corp.

B2Gold Corp.

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; other mineral properties; and corporate and other. It generates maximum revenue from the Fekola mine segment in Mali.

Newmont Announces a Decrease in its Holdings of Discovery Silver Corp.

Early Warning Disclosure

Newmont Corporation (NYSE: NEM) (TSX: NGT) (ASX: NEM) (PNGX: NEM) ("Newmont" or the "Company") announced today a decrease in its holdings of common shares (" Common Shares ") in the capital of Discovery Silver Corp. (" Discovery ").

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Barrick Is Now 'B' on the NYSE

Barrick Mining Corporation (NYSE:B)(TSX:ABX) is now trading under the single-letter ticker symbol ‘B' on the New York Stock Exchange, reinforcing the Company's position as a global gold and copper mining leader.

In celebration of this milestone, Barrick president and chief executive Mark Bristow rang The Opening Bell® at the NYSE this morning.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Abcourt Intersects 24.3 g/t Over 1.9 m Including 41.9 g/t Over 0.6 m in the 785N Zone and Provides an Update on Its Sleeping Giant Activities

Abcourt Mines Inc. ("Abcourt" or the "Corporation") (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to report new drilling results and an update on its activities at the Sleeping Giant mine.

In 2025, Abcourt completed 36 underground drill holes totaling 5,632 meters. Of these holes, seven target the 785N zone and the underlying areas for a total of 3,316 meters. This 785N zone is in a new sector to the east and at depth of the developed sectors of the mine. After releasing the results of two of these holes earlier this year, Abcourt is today releasing the results of two more holes, 78-888 and 78-890.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×